Syndax Pharmaceuticals (id:7683 SNDX)
16.09 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 8:28:42 AM)
Exchange closed, opens in 1 day 1 hour
About Syndax Pharmaceuticals
Market Capitalization 1.38B
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
35 Gatehouse Drive Waltham 02451 MA United States |
| Phone | 781 419 1400 |
| Website | https://www.syndax.com |
| Employees | 184 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | SNDX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 15.00 - 25.34 |
| Market Capitalization | 1.38B |
| P/E trailing | -5.40 |
| P/E forward | -4.55 |
| Price/Sale | 85.94 |
| Price/Book | 3.76 |
| Beta | 0.917 |
| EPS | -3.64 |
| EPS United States (ID:6, base:3402) | 24.22 |